Compare KVHI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | MCRB |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.4M | 139.7M |
| IPO Year | 1996 | 2015 |
| Metric | KVHI | MCRB |
|---|---|---|
| Price | $5.99 | $8.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 45.8K | ★ 93.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.63 | ★ 100.00 |
| EPS | N/A | ★ 2.40 |
| Revenue | $9,622,000.00 | ★ $126,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.15 | N/A |
| P/E Ratio | ★ N/A | $3.43 |
| Revenue Growth | 3.82 | ★ 1672.24 |
| 52 Week Low | $4.80 | $0.36 |
| 52 Week High | $7.71 | $29.98 |
| Indicator | KVHI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 26.09 |
| Support Level | $5.80 | $7.12 |
| Resistance Level | $6.27 | $8.49 |
| Average True Range (ATR) | 0.39 | 1.13 |
| MACD | -0.01 | -0.42 |
| Stochastic Oscillator | 30.93 | 5.42 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.